Clinical trials
Ductal Carcinoma in Situ clinical trials
Below are recruiting ductal carcinoma in situ clinical trials, each written for real people, not researchers. We’re tracking 51 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06902311RecruitingPhase 2
Shorter radiation after lumpectomy for early breast cancer
This trial tests a shorter, more intense course of daily radiation therapy (called ultra hypo-fractionation) given after lumpectomy for early-stage breast cancer. The goal is to reduce the number of treatment visits while keeping the same high level of effectiveness and safety.
Chapel Hill, North CarolinaAges 50 years+ - NCT06903468Recruiting
New cavity marking technique for breast cancer surgery and radiation
This trial tests a new way to mark the area where breast cancer is removed during lumpectomy with oncoplastic reconstruction. The goal is to make follow-up radiation more precise and reduce the need for additional surgeries.
Gainesville, FloridaAges 18 years+ - NCT07095114Recruiting
Disappearing markers for daily breast radiation
This study tests whether small disappearing ink marks can be used to guide daily radiation treatments for breast cancer. It may help make radiation more precise and comfortable.
Detroit, MichiganAges 18 years+ - NCT02389673Recruiting
Radiation during breast surgery for low-grade DCIS
This trial studies giving radiation during surgery for women with a certain early breast condition called ductal carcinoma in situ (DCIS). It may help lower the chance that the DCIS comes back, especially when combined with breast-conserving surgery.
Guangzhou, GuangdongAges 18–70 - NCT07478016Recruiting
Studying inflammation and social factors in breast cancer
This study looks at how inflammation and social factors (like stress or support) affect breast cancer patients before they start treatment. You may qualify if you are a woman, newly diagnosed, and have not yet had any cancer treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07507890Recruiting
Nipple-sparing mastectomy through one armpit incision
This trial tests a less invasive surgery for early-stage breast cancer that removes breast tissue through a single small cut in the armpit while keeping the nipple. It may be an option for women with small to medium breasts who are candidates for immediate breast reconstruction.
Candiolo, TurinAges 18 years+ - NCT03448926Recruiting
DCIS test registry to guide radiation and drug decisions
This study collects information from people with breast ductal carcinoma in situ (DCIS) to see how a specific lab test (DCISionRT) may help predict who benefits from radiation and/or certain medications. Your results and clinical details are gathered during routine care, not necessarily to change treatment right away.
Scottsdale, ArizonaAges 30–85 - NCT06984250Recruiting
Shorter radiation with extra focus on tumor site for breast cancer
This trial tests a shorter course of radiation therapy that includes an extra dose to the tumor site for women with early-stage breast cancer. It aims to make treatment more convenient and effective after breast-conserving surgery.
Taipei, TaiwanAges 20–85 - NCT05178498Recruiting
Diet and inflammation score in women at high breast cancer risk
This study looks at whether a person’s diet that tends to cause more body inflammation is linked to future breast cancer risk. It may help researchers understand how eating patterns could affect risk in people already considered high-risk.
Columbus, OhioAges 18 years+ - NCT06882746RecruitingPhase 1
Testing different doses of BI 765049 for advanced colorectal, stomach, or pancreatic cancer
This study tests a new drug (BI 765049) at different doses for people with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The goal is to find a safe and effective dose.
Los Angeles, CaliforniaAges 18 years+ - NCT04790305RecruitingPhase 4
Huaier granules with standard therapy for early triple-negative breast cancer
This trial looks at whether adding Huaier granules to usual after-surgery treatment can improve outcomes for people with high-risk early-stage triple-negative breast cancer. It focuses on whether the added supplement is safe and helpful after standard care.
Hefei, AnhuiAges 18–70 - NCT05288205RecruitingPhase 1/Phase 2
JAB-21822 plus JAB-3312 for KRAS G12C solid tumors
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT07214532Recruiting
Guiding CDK4/6 inhibitor use by a blood test in breast cancer
This trial is for women and men with early-stage, hormone-positive, HER2-negative breast cancer. It uses a blood test (Signatera) to detect tiny amounts of cancer DNA and only starts a CDK4/6 inhibitor (ribociclib or abemaciclib) if the test shows cancer DNA is present.
Birmingham, AlabamaAges 18 years+ - NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
Boston, MassachusettsAges 18 years+ - NCT05475366Recruiting
Choosing the right first chemotherapy for advanced pancreatic cancer
This trial tests a personalized approach to selecting your first chemotherapy based on tumor gene activity. It aims to match treatment to your cancer’s biology to improve outcomes for people with advanced (metastatic) pancreatic cancer.
ClichyAges 18–75 - NCT06115486Recruiting
Exercise to improve muscle after breast cancer treatment
This trial tests whether a structured exercise program (called EXERT-BCH) can help improve muscle mass in women who have finished breast cancer treatment. It involves group resistance training sessions and is designed to support recovery and strength.
Pittsburgh, PennsylvaniaAges 20–89 - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT06401304Recruiting
Value-based breast surgery outcomes study
This study looks at how well breast-conserving surgery (lumpectomy) works for women with breast cancer or other breast conditions. It will track how you feel, how you look, and your overall satisfaction to help improve future care.
SydneyAges 18 years+ - NCT02620852Recruiting
Wisdom Study: Women’s breast cancer screening decisions
This study looks at how to decide the best breast cancer screening (like mammograms) based on your personal risk. It may help by testing a smarter way to match screening to your risk level.
Birmingham, AlabamaAges 30–74 - NCT07432633RecruitingPhase 1/Phase 2
Imaging scan to detect cancer-linked protein in several tumor types
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
Dallas, TexasAges 18–80 - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+
Hear when a new Ductal Carcinoma in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ductal carcinoma in situ?
- Yes. Clin2 currently lists 51 recruiting ductal carcinoma in situ studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ductal carcinoma in situ trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ductal carcinoma in situ trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.